Ann: A$18.7m Osteopore, NDCS and A*STAR project hits milestones, page-38

I like the potential but I don’t see them making big dollars having trials in Singapore. The dental industry is very hard to break into and having some development coming from Singapore which still needs another 3 years for human testing doesn’t make sense. If they did it in Australia they have the rebates, global recognition, fast track FDA and hit bigger markets and more funding opportunities. Just weird they went down this path. Maybe it’s an ethical issue with the type of trials they are doing and hence easier for ethical approval in Singapore.